The Gerresheimer
Group has set up a new facility for medical plastic systems in
Indaiatuba (Brazil). The plant is to commence operations early in
2010. On the basis of a long-term cooperation agreement with Novo
Nordisk, components will be produced with state-of-the-art technology
for insulin pen systems for diabetics.
Insulin pens are
drug-delivery devices in ball-point pen format which allow diabetes
patients to inject themselves with the regularly required insulin dose
safely and almost painlessly. Novo Nordisk has a large insulin plant
in Brazil which will in future be supplied locally by the new
technology center of the Gerresheimer Group. For Gerresheimer this is
already the fourth production plant in South America in addition to
two existing plants for standardized pharma plastic packaging in
Brazil and one in Argentina.
Apart from the new
production facility in Brazil, Gerresheimer already has two other
production facilities for pen systems in Europe.
Gerresheimer
employs around 10,000 people in 40 locations in Europe, America and
Asia. In the financial year 2008, worldwide sales totaled €1.06bn. The
product portfolio ranges from pharmaceutical vials made of glass and
plastic through to complex drug-delivery systems for the pharma &
healthcare industry. These include sterile syringes, inhalers and
other system-based approaches for safe dosage and application of
medications. The Group enjoys a leading position in markets which are
characterized by high technical and regulatory barriers.
For more
information, visit
www.gerresheimer.com.